Drug Discovery World

OCTOBER 26, 2022

As part of the collaboration with Dr Salha Bujassoum, Senior Consultant and Clinical Lead of the Cancer Genetic & Breast Cancer Programme at HMC’s National Center for Cancer Care and Research (NCCCR), Qatar Biobank participants carrying pathogenic germline Breast Cancer gene (BRCA) variants were identified.

Genome 52

Genome Genomics Biobanking Genetics 52

Drug Discovery World

NOVEMBER 7, 2022

This population-based project aims to position Qatar among the countries successfully implementing precision medicine for better health outcomes, and is generating large databases which combine WGS and other omics data with the comprehensive phenotypic data collected at Qatar Biobank. . References .

Genome 98

Genome Genomics Development Genetics 98

XTalks

SEPTEMBER 16, 2022

Having a mutation in one copy of either the EGFR and/or KRAS gene isn’t enough to lead to lung cancer. Most cancers follow the double-hit model where a mutation in the second copy of the gene is required for the cancer to form. This means that a drug like an IL-1? The Double Hit. Results of the investigations showed that PM 2.5

Research 97

Research Gene Scientist Biobanking 97

Delveinsight

MARCH 2, 2021

Chinook will have access to the NURTuRE cohort study along with other proprietary patient biobanks and Evotec’s multi-omics integration platform, and the company plans to potentially deliver targeted therapies in rare kidney diseases such as IgA nephropathy and glomerular diseases.

Drug Delivery 40

Drug Delivery Research Drugs Gene Editing 40

XTalks

APRIL 15, 2021

Experts from Servier and Genuity Science recently spoke on a webinar about using genomics data to drive drug development in heart failure and identify new targets for novel therapeutics. However, these drugs have shown limited effectiveness in treating HFpEF. Case Study: Genomic Approaches in Coronary Artery Disease Drug Development.

Development 98

Development Drugs Genome Genomics 98

The Pharma Data

APRIL 11, 2023

In the New Drugs on the Horizon session at AACR, Bayer will present preclinical data on its novel selective diacylglycerol kinase (DGK) zeta inhibitor BAY 2965501, which is under Phase 1 clinical evaluation. These results, along with a mathematical model-informed approach have supported the currently ongoing dose expansion for BAY 2416964.

Research 40

Research Clinical Trials Clinical Trials Trials 40

The Pharma Data

JULY 8, 2021

Managed by the Broad Institute of MIT and Harvard, the browser gives access to results from analyses of whole exome sequencing data from 300,000 UK Biobank research participants. (Nasdaq: BIIB) and Pfizer (NYSE: PFE). These genetic data have been paired with detailed health information to create this browsable resource.

Genetics 52

Genetics Biobanking Protein Containment 52

Drug Discovery World

OCTOBER 30, 2023

We previously conducted a hypothesis-free study using genotype data from the UK Biobank, which resulted in the first mechanism-based stratification of endometriosis patients. SG: Chronic diseases, like endometriosis, are polygenic, caused by a complex interplay of multiple genes and other factors.

Genome 72

Genome Genomics Genotype Clinical Trials 72

Drug Discovery World

JANUARY 24, 2024

Wigerinck has taken four drugs (Prezista, Olysio, Jyseleca and Rekambys) to market. Phase I of the clinical program will dose healthy volunteers with single ascending doses of FIB992 before proceeding to a multiple ascending dose study where the drug is administered for a two-week period.

Research 59

Research Gene Expression Drugs Development 59